Auriga Partners is the famous VC, which was founded in 1998. The venture was found in Europe in France. The main department of described VC is located in the Paris.
Among the most successful fund investment fields, there are Medical Device, Medical. Besides, a startup requires to be at the age of 11-15 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Nexthink, Ekinops, Hybrigenics. For fund there is a match between the location of its establishment and the land of its numerous investments - France. The fund has no specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low.
The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the Auriga Partners, startups are often financed by Omnes Capital, Bpifrance, XAnge. The meaningful sponsors for the fund in investment in the same round are Sofinnova Partners, Bpifrance, 123Venture. In the next rounds fund is usually obtained by Omnes Capital, 123Venture, Wellington Partners.
The fund is constantly included in 7-12 investment rounds annually. The top amount of exits for fund were in 2017. This Auriga Partners works on 9 percentage points less the average amount of lead investments comparing to the other organizations. The real fund results show that this VC is 12 percentage points less often commits exit comparing to other companies. The important activity for fund was in 2007. The common things for fund are deals in the range of 10 - 50 millions dollars.
This organization was formed by Bernard Daugeras, Jacques Chatain, Patrick Bamas. The overall number of key employees were 8.
Related Funds
Funds with similar focus
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Exeliom | $9M | 30 Jun 2023 | Dijon, Bourgogne-Franche-Comté, France | ||
Patrowl | $2M | 24 Jun 2022 | Paris, Ile-de-France, France | ||
Nexthink | $86M | 12 Dec 2018 | Switzerland, " Switzerland"} | ||
Exeliom | $8M | 06 Jul 2018 | Dijon, Bourgogne-Franche-Comté, France | ||
EnobraQ | $3M | 10 Apr 2018 | France, Auvergne-Rhône-Alpes, France | ||
Pherecydes Pharma | $10M | 16 Jan 2018 | France, Ile-de-France, France | ||
aveni | $10M | 24 Oct 2017 | France, Ile-de-France, France | ||
VitaDX | $1M | 06 Jun 2017 | France, Ile-de-France | ||
One More Company | 01 Jun 2016 | New York, New York, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Exeliom | $9M | 30 Jun 2023 | Dijon, Bourgogne-Franche-Comté, France | ||
Patrowl | $2M | 24 Jun 2022 | Paris, Ile-de-France, France | ||
Nexthink | $86M | 12 Dec 2018 | Switzerland, " Switzerland"} | ||
Exeliom | $8M | 06 Jul 2018 | Dijon, Bourgogne-Franche-Comté, France | ||
EnobraQ | $3M | 10 Apr 2018 | France, Auvergne-Rhône-Alpes, France | ||
Pherecydes Pharma | $10M | 16 Jan 2018 | France, Ile-de-France, France | ||
aveni | $10M | 24 Oct 2017 | France, Ile-de-France, France | ||
VitaDX | $1M | 06 Jun 2017 | France, Ile-de-France | ||
One More Company | 01 Jun 2016 | New York, New York, United States |